GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (XBUL:LLY) » Definitions » Cyclically Adjusted Revenue per Share

Eli Lilly and Co (XBUL:LLY) Cyclically Adjusted Revenue per Share : лв30.61 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share for the three months ended in Dec. 2024 was лв26.045. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is лв30.61 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Eli Lilly and Co's average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Eli Lilly and Co was 9.50% per year. The lowest was 1.80% per year. And the median was 7.10% per year.

As of today (2025-05-10), Eli Lilly and Co's current stock price is лв850.20. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was лв30.61. Eli Lilly and Co's Cyclically Adjusted PS Ratio of today is 27.78.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eli Lilly and Co was 31.37. The lowest was 3.23. And the median was 6.45.


Eli Lilly and Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted Revenue per Share Chart

Eli Lilly and Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 30.61

Eli Lilly and Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 27.24 29.02 30.61

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.


;
;

Eli Lilly and Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=26.045/133.1571*133.1571
=26.045

Current CPI (Dec. 2024) = 133.1571.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 7.566 99.621 10.113
201506 8.120 100.684 10.739
201509 8.092 100.392 10.733
201512 8.774 99.792 11.708
201603 7.954 100.470 10.542
201606 8.861 101.688 11.603
201609 8.506 101.861 11.119
201612 9.410 101.863 12.301
201703 8.602 102.862 11.135
201706 9.576 103.349 12.338
201709 9.312 104.136 11.907
201712 5.434 104.011 6.957
201803 8.218 105.290 10.393
201806 9.422 106.317 11.801
201809 8.987 106.507 11.236
201812 9.594 105.998 12.052
201903 8.994 107.251 11.167
201906 10.595 108.070 13.055
201909 10.363 108.329 12.738
201912 11.606 108.420 14.254
202003 11.171 108.902 13.659
202006 10.493 108.767 12.846
202009 10.947 109.815 13.274
202012 14.142 109.897 17.135
202103 12.964 111.754 15.447
202106 12.867 114.631 14.946
202109 12.924 115.734 14.870
202112 15.019 117.630 17.002
202203 14.975 121.301 16.439
202206 12.489 125.017 13.302
202209 13.349 125.227 14.194
202212 14.023 125.222 14.912
202303 13.391 127.348 14.002
202306 16.004 128.729 16.555
202309 18.347 129.860 18.813
202312 17.986 129.419 18.505
202403 16.861 131.776 17.038
202406 21.726 132.554 21.825
202409 21.968 133.029 21.989
202412 26.045 133.157 26.045

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Eli Lilly and Co  (XBUL:LLY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=850.20/30.61
=27.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eli Lilly and Co was 31.37. The lowest was 3.23. And the median was 6.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Eli Lilly and Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co Business Description

Industry
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.